PT Kalbe Farma Tbk · IDX:KLBF

PT Kalbe Farma Tbk — FY2021 Earnings Presentation

44 slides from PT Kalbe Farma Tbk's earnings presentation, March 2022

  1. Slide 1: Company Update FY 2021 Audited Results

    Company Update FY 2021 Audited Results PT Kalbe Farma Tbk March 2022

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation has been prepared for informational purposes only by PT.Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2021 audited results of the Company. The information conta

  3. Slide 3: Key Updates Business Overview Financial Overview

    Key Updates 4 Business Overview 12 Financial Overview 25 Appendix 32

  4. Slide 4: Key Updates

    (S KALBE Key Updates THRIVE THROUGH INNOVATION & DIGITALIZATION

  5. Slide 5: FY 2021 Audited Results

    FY 2021 Audited Results Growth Challenges Solid top line growth of 13.6% supported by organic volume growth and broad based growth improvement in FY 2021 Volatile economy Strong net income growth of 16.5% that influenced purchasing power Prudent operational efficiency. EPS reached Rp 67.9 as of YTD

  6. Slide 6: Fast Response in Volatile Conditions

    Fast Response in Volatile Conditions Diagnostics Vaccine & Curative Products Vaccine Distribution GX-19N vaccine RT-PCR test & RT LAMP method (repurpose the development Fluvir, Covifor, Favikal Reach more than 1000 government for DNA based vaccines) hospitals in 7 provinces . Vitamins/Supplements He

  7. Slide 7: Innovation for Sustainable Growth

    Innovation for Sustainable Growth Specialty Insulin monoclonal antibodies (mAbs) & Biosimilar Diagnostic Vaccine Preventive Herbal Vitamins/Supplements Affordable Unbranded Generic Chilgo Powder Herbal Digital

  8. Slide 8: Focus on Customer Needs

    Focus on Customer Needs KALBE

  9. Slide 9: Online Digital Solution

    Online Digital Solution Telemedicine providing health consultation with doctors and health experts, pharmacy platform and e-commerce for healthcare and wellness products > 14mn users > 465k consultation > 20k doctors Place Your Place Your B2B order management platform for healthcare Place Your Pictu

  10. Slide 10: Strengthening Our Human Capital

    Strengthening Our Human Capital KMMP : Kalbe Middle Management Program Health & Mindfulness Meditation KFMP : Kalbe First Line Management Program Leader as Coach Kampus Merdeka Program Kalbe collaborates with the Ministry of Education and Culture, Research and Technology in the Merdeka Indonesia Jay

  11. Slide 11: Access to Healthcare for a Better Life

    Access to Healthcare for a Better Life • Increase generic products (>50%), medical devices and diagnostics to support the National Health Insurance scheme • Fight against stunting, supporting nutrition for mothers and children in collaboration with BKKBN (National Family Planning Indonesia) Fast Res

  12. Slide 12: Business Overview

    (S KALBE Business Overview THRIVE THROUGH INNOVATION & DIGITALIZATION

  13. Slide 13: Segment & Geographic Breakdown

    Segment & Geographic Breakdown • Established in 1966 and headquartered in Jakarta • A public company since 1991 and listed in the Indonesia Stock Exchange – free float stocks (public) 42.08%* • The largest publicly-listed pharmaceuticals company in 5% Southeast Asia – market cap 5.3 billion USD* exp

  14. Slide 14: Prescription Pharmaceuticals Division

    Prescription Pharmaceuticals Division 14.8% • No. 1 player in Indonesian prescription pharma market • Performs better than pharma market 5,719 4,984 • Provides access to healthcare through unbranded generic – BPJS program • Expands to specialty products (oncology and biologic) • Creates total health

  15. Slide 15: Prescription Pharmaceuticals Division

    Prescription Pharmaceuticals Division Expanding Access to Healthcare - National Health Insurance Program • Selection of focused categories to achieve scale • Dedicated unbranded generic plant Expanding Collaboration in Specialty Category Oncology Products Other Products Biological based Products

  16. Slide 16: Biologics Journey

    Biologics Journey Strengthening Presence in Specialty Products • Focus on immuno-oncology products portfolio • Raised USD 105mn from Kalbe, General Atlantic (GA) • Henlius - HLX10 and Genexine in 2021 • IMAB - two molecules • Business expansion through engagement with • Ongoing clinical development

  17. Slide 17: Consumer Health Division

    Consumer Health Division +7.1% • No. 1 Player in OTC market and Health Supplement category 3,382 3,623 • Gross Profit Margin YTD 12 2021 is increased to 59.0% from 57.8% in YTD 12 2020, due to products mix. • Strengthening products in vitamin and supplement with the support of scientific information

  18. Slide 18: Consumer Health Division

    Consumer Health Division Therapeutic Class Kalbe’s Product Market Share 2020 OTC - Antacids Promag 72% OTC – Anti Diarrhea Neo Entrostop 56% OTC – Cough Remedies Komix, Woods 50% OTC – Cold Remedies Mixagrip, Procold 39% OTC – Children Multivitamin (tablet) Sakatonik ABC 52% Health Supplement Extra

  19. Slide 19: Consumer Health Division

    Consumer Health Division ● New products development in 2020 & 2021 are focused on the multivitamin and mineral category Sakatonik Activ D3 1000 IU Xonce 1000 mg Kaplet Komix Herbal for Kids Fatigon Promuno H2 - Cordyceps Femmy D3 1000 IU Femmy Trimune Entrostop Herbal Bejo for Kids Bejo Sujamer ● Co

  20. Slide 20: Herbal Development

    Herbal Development Red Ginger & Citronella Building red ginger ecosystem, Kalbe engages with more than 10k farmers across Indonesia Kalbe conducted a lab-scale trial of the clean production red ginger extraction method with both fresh red ginger and dried red ginger, in collaboration with Institut P

  21. Slide 21: Nutritionals Division

    Nutritionals Division Strong brand awareness of existing major products 2.5% • Gross Profit Margin YTD 12 2021 declined to 51.5% from 6,994 7,166 53.0% in YTD 12 2020 due to product mix • Offers more affordable products to serve market needs (Zee & Chil Go Powder) • Performs better than powdered mil

  22. Slide 22: Nutritionals Division

    Nutritionals Division Catered to expecting & lactating mothers, babies, toddlers, children, teens and adults

  23. Slide 23: Distribution & Logistics Division

    Distribution & Logistics Division +25.8% • Managed by PT Enseval Putera Megatrading Tbk (EPMT.JK), a listed subsidiary company (92.47% owned). 9,752 7,752 • Net sales represents the 3rd party product sales and distribution margin of internal product sales for consolidated accounting purposes. • Gros

  24. Slide 24: Distribution & Logistics Division

    Distribution & Logistics Division The Most Extensive Distribution Network Medical Devices • Completion of surgical suture production facility to comply with local content regulation • Building own brand “E-Care” for consumables products and “Elvasense” for personal healthcare & diagnostic kit produc

  25. Slide 25: Financial Overview

    (S KALBE Financial Overview THRIVE THROUGH INNOVATION & DIGITALIZATION

  26. Slide 26: Consolidated Operational Performance

    Consolidated Operational Performance Net Sales (in Rp Bn) +13.6% 31 Dec 2020 31 Dec 2021 (Audited) (Unaudited) 26.261 23,113 +25.8% Growth +14.8% +7.1% +2.5% 9.752 6,994 7,166 7,752 4,984 5,719 3,382 3,623 PRESCRIPTION CONSUMER NUTRITIONALS DISTRIBUTION CONSOLIDATED PHARMACEUTICALS HEALTH & LOGISTIC

  27. Slide 27: Consolidated Operational Performance

    Consolidated Operational Performance Gross Profit (in Rp Bn) Operating Expenses to Net Sales Ratio (%) 28.9% 27.7% +10.1% 1.2% 1.1% Research & GPM (%) 44.3% 43.0% 6.0% 5,4% Development General & Administrative 10,246 11.284 21.7% 21,1% Selling Expenses 31 Dec 2020 31 Dec 2021 31 Dec 2020 31 Dec 2021

  28. Slide 28: Consolidated Operational Performance

    Consolidated Operational Performance Income Before Tax (in Rp Bn) Net Income (in Rp Bn) +14.2% +16.5% Income before Net Income 15.7% 15.8% Margin (%) 11.8% 12.1% Tax Margin (%) 4.143 3,184 3,628 2,733 31 Dec 2020 31 Dec 2021 31 Dec 2020 31 Dec 2021 (Audited) (Unaudited) (Audited) (Audited) • Positiv

  29. Slide 29: Working Capital Management

    Working Capital Management Managing Net Operating Cycle 136 131 126 120 129 Net Operating Cycle has increased from 120 to 129 days 124 122 111 109 101 Improve working capital through building 56 57 54 strong relationship with clients and 51 47 suppliers 38 41 35 40 35 Ensure product availability thr

  30. Slide 30: Capital Allocation

    Capital Allocation * All in Rp Billion except for gearing ratio, dividend payout ratio, and dividend yield Total Debt and Gearing Ratio Cash & Net Cash Balance 1,092 817 6,216 5,208 5,633 5.9% 584 4,116 319 357 4.9% 3,153 3,040 2785 2,466 2,796 2,223 2.3% 2.3% 2.7% 2017 2018 2019 2020 2021 2017 2018

  31. Slide 31: Outlook 2022

    Outlook 2022 YoY Sales Growth EPS Growth Dividend Payout 11-15% 11-15% Ratio FY21: 16.5% 45-55% FY21: 13.6% • 14,500 USD/IDR exchange rate • 5% - 5.5% Indonesia GDP growth • Capex of Rp 1.0 Tn for production capacity, distribution and network expansion • Share buyback program to strengthen sharehold

  32. Slide 32: Appendix

    (S KALBE Appendix THRIVE THROUGH INNOVATION & DIGITALIZATION

  33. Slide 33: Macro Overview

    Macro Overview NATIONAL HEALTH INSURANCE (JKN) COVERAGE 2014 133mn people 2015 158mn people 2016 170mn people 2017 188mn people 2018 216mn people 2019 221mn people 2020 222mn people 2021* 230mn people Source : BPJS Kesehatan * As of November 2021 HEALTHCARE ALLOCATION IN 2020 GOVERNMENT BUDGET Handl

  34. Slide 34: Macro Overview

    Macro Overview INDONESIA GDP GROWTH GDP GROWTH (%) INFLATION (%) EXCHANGE RATE (Rupiah / USD) The momentum for economic The inflation rate in The rupiah exchange rate in recovery is expected to 2022 is expected to 2022 is expected to be continue in 2022, among strengthen in line maintained in the le

  35. Slide 35: Macro Overview

    Macro Overview Recent Pharma Regulations : Government Regulation No. 45 Year 2019 • Super deduction of R&D cost (PMK 153 year 2020) and vocational training cost (PMK 128 year 2019) which will lower the tax base for corporate income tax calculation. Perppu No. 1 Year 2020 • Regarding the reduction of

  36. Slide 36: ESG Achievements and Activities

    ESG Achievements and Activities SUSTAINABILITY REPORT KALBE Bisnis Indonesia CSR Award 2021 Kalbe has started Sustainability Report “Platinum Champion since 2017, prepared based on the Global In Corporate Social Reporting Initiatives (GRI) guidelines Responsibility https://www.kalbe.co.id/investor/f

  37. Slide 37: Appendix

    (S KALBE Appendix 2 THRIVE THROUGH INNOVATION & DIGITALIZATION

  38. Slide 38: Consolidated Statement of Financial Position

    CONSOLIDATED STATEMENT OF FINANCIAL POSITION Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change ASSETS CURRENT ASSETS Cash and Cash Equivalents 6.216.247.801.928 5.207.929.420.504 19,4% Trade Receivables 3.431.018.099.213 3.477.220.762.616 -1,3% Other Receivables 114.124.556.39

  39. Slide 39: Consolidated Statement of Financial Position

    CONSOLIDATED STATEMENT OF FINANCIAL POSITION Expressed in Rupiah 31 Dec 2021 31 Dec 2020 % Change (Audited) (Audited) LIABILITIES CURRENT LIABILITIES Short-term Bank Loans - 220.500.000.000 -100,0% Trade Payables 1.667.595.790.804 1.240.385.598.118 34,4% Other Payables 710.888.106.011 656.249.988.65

  40. Slide 40: Consolidated Statement of Profit or Loss and Other Comprehensive Income

    CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change NET SALES 26.261.194.512.313 23.112.654.991.224 13,6% COST OF GOODS SOLD 14.977.410.271.049 12.866.332.497.453 16,4% % to NS 55,6% 55,7% GROSS PROFIT 11.28

  41. Slide 41: Consolidated Statement of Profit or Loss and Other Comprehensive Income

    CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change INCOME TAX EXPENSE, NET (911.256.951.493) (828.010.058.930) 10,1% % to NS -3,7% -3,6% INCOME FOR THE YEAR 3.232.007.683.281 2.799.622.515.814 15,4% % to NS

  42. Slide 42: Consolidated Statement of Cash Flows

    CONSOLIDATED STATEMENT OF CASH FLOWS Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change CASH FLOWS FROM OPERATING ACTIVITIES Cash Received from Customers 28.936.595.007.408 25.453.548.262.874 13,7% Cash Payments to Suppliers and Employees (18.765.991.549.730) (15.295.694.265.14

  43. Slide 43: Consolidated Statement of Cash Flows

    CONSOLIDATED STATEMENT OF CASH FLOWS Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change CASH FLOWS FROM FINANCING ACTIVITIES Receipt of Capital Contributions from Subsidiary’s Non-controlling Interests 1.227.271.550.000 - 100,0% Proceeds from Short-term Bank Loans 136.100.000.0

  44. Slide 44: Thank You

    THRIVE THROUGH INNOVATION & DIGITALIZATION KALBE™ ges - |:

PT Kalbe Farma — FY2021 Earnings Presentation on 6ix